Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 561-567

  Dagne, Abaineh ^a   Melkamu, Tamene ^b   Schutten, Melissa M ^a,b   Qian, Xuemin ^a   Upadhyaya, Pramod ^a   Luo, Xianghua ^a,c   Kassie, Fekadu ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SILIBININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; NITROSAMINES; PROTO-ONCOGENE PROTEINS C-AKT; SILYMARIN;

EID: 79953713679     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr010     Document Type: Article

References (35)

1. Jemal,A. et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249.
2. Thompson,I.M. et al. (2003) The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 349, 215-224.
3. Meyskens,F.L. Jr. et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebocontrolled, double-blind trial. Cancer Prev. Res. (Phila.), 1, 32-38.
4. Kinsinger,L.S. et al. (2002) Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med., 137, 59-69.
5. Hoffmann,D. et al. (1997) The changing cigarette, 1950-1995. J. Toxicol. Environ. Health, 50, 307-364.
6. Rodgman,A. et al. (2009) The Chemical Components of Tobacco and Tobacco Smoke. CRC Press, Boca Raton, FL.
7. Vang,O. et al. (1996) Naturally Occurring Antimutagens. III. Indoles. Nordic Council of Ministers, Copenhagen, Denmark.
8. International Agency for Research on Cancer. (2004) Cruciferous Vegetables, Isothiocyanates, and Indoles. IARC Handbooks of Cancer Prevention., Vol. 9, IARC, Lyon, pp. 171-176.
9. Rahman,K.M. et al. (2000) Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene, 19, 5764-5771.
10. Rahman,K.M. et al. (2004) Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr. Cancer, 48, 84-94.
11. Rahman,K.M. et al. (2006) Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol. Cancer Ther., 5, 2747-2756.
12. Aggarwal,B.B. et al. (2005) Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 4, 1201-1215.
13. Anderton,M.J. et al. (2004) Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin. Cancer Res., 10, 5233-5241.
14. Bjeldanes,L.F. et al. (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl Acad. Sci. USA, 88, 9543-9547.
15. Wellington,K. et al. (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs, 15, 465-489.
16. Agarwal,R. et al. (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res., 26, 4457-4498.
17. Singh,R.P. et al. (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl Cancer Inst., 98, 846-855.
18. Agarwal,C. et al. (2003) Silibinin upregulates the expression of cyclindependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 22, 8271-8282.
19. Kassie,F. et al. (2008) Dose-dependent inhibition of tobacco smoke carcinogen-induced lung tumorigenesis in A/J mice by indole-3-carbinol. Cancer Prev. Res. (Phila.), 1, 568-576.
20. Kassie,F. et al. (2010) Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis, 31, 239-245.
21. Hecht,S.S. et al. (1983) Effects of a-deuterium substitution on the mutagenicity of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis, 4, 305-310.
22. Reeves,P.G. et al. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr., 123, 1939-1951.
23. Kassie,F. et al. (2008) Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogeninduced lung adenocarcinoma in mice. Cancer Prev. Res. (Phila.), 1, 285-297.
24. Nikitin,A.Y. et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res., 64, 2307-2316.
25. Nakamura,Y. et al. (2009) A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol. Cancer, 8, 100.
26. Choi,H.S. et al. (2010) Indole-3-carbinol induces apoptosis through p.53 and activation of caspase-8 pathway in lung cancer A549 cells. Food Chem. Toxicol., 48, 883-890.
27. Mateen,S. et al. (2010) Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol. Carcinog., 49, 247-258.
28. Reagan-Shaw,S. et al. (2008) Dose translation from animal to human studies revisited. FASEB J., 22, 659-661.
29. Reed,G.A. et al. (2005) A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol. Biomarkers Prev., 14, 1953-1960.
30. Bradlow,H.L. et al. (2010) Diindolylmethane (DIM) spontaneously forms from indole-3-carbinol (I3C) during cell culture experiments. In Vivo, 24, 387-391.
31. Singh,R.P. et al. (2002) Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res., 62, 3063-3069.
32. Sato,M. et al. (2006) Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res., 66, 2116-2128.
33. Matzinger,S.A. et al. (1995) K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis, 16, 2487-2492.
34. Engelman,J.A. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med., 14, 1351-1356.
35. Ramasamy,K. et al. (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett., 269, 352-362.